Inari Medical Reports Fourth Quarter 2023 Financial Results

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) reported strong financial results for Q4 and full year 2023, with revenue reaching $132.1 million in Q4, a 22.6% increase over the previous year. The company closed the LimFlow acquisition and completed enrollment in the PEERLESS trial. Inari expects revenue of $580-595 million for 2024, aiming for sustained operating profitability in the first half of 2025.

Positive

• Revenue for Q4 2023 was $132.1 million, a 22.6% increase over Q4 2022.
• GAAP operating loss was $9.3 million in Q4 2023, compared to $5.9 million in Q4 2022.
• Non-GAAP operating loss was $0.3 million in Q4 2023, compared to $5.9 million in Q4 2022.
• Inari closed the LimFlow acquisition on November 15, 2023.
• The company completed enrollment in the PEERLESS randomized controlled trial.
• Full year 2023 revenue was $493.6 million, up 28.7% from the prior year.
• Inari expects revenue of $580-595 million for full year 2024, with a target of achieving sustained operating profitability in the first half of 2025.

Negative

• None.

Financial Analyst

The reported revenue growth of 22.6% for Inari Medical's fourth quarter and 28.7% for the full year is a strong indicator of the company's market penetration and the successful adoption of its medical procedures. The detailed financial results, including the gross margin remaining robust at around 87% despite scaling operations, suggest efficient cost management and a potentially sustainable business model. However, the GAAP operating losses reported both quarterly and annually, although narrower year-over-year, highlight ongoing investments in expansion and R&D. This is a critical consideration for investors, as it suggests a strategic prioritization of growth over immediate profitability, which is often the case in the medical device industry.

Furthermore, the LimFlow acquisition and related costs, although contributing to the operating loss, represent strategic positioning in the market. The acquisition is likely to enhance Inari's product portfolio and could lead to long-term revenue growth. The company's projection of reaching sustained operating profitability by the first half of 2025 can be interpreted as a confident outlook on the success of these investments. However, it is essential for stakeholders to monitor the integration of LimFlow and the subsequent financial impact to assess the accuracy of these projections.

Medical Research Analyst

The completion of enrollment in the PEERLESS randomized controlled trial (RCT) is a significant milestone for Inari Medical. RCTs are the gold standard for evaluating the efficacy and safety of medical treatments. Successful trial outcomes can lead to increased market adoption and potentially drive revenue growth. The emphasis on generating high-level clinical evidence is a positive sign for healthcare professionals and patients, indicating a commitment to proving the value and effectiveness of Inari's therapies.

From a research perspective, the ability to establish their therapy as a standard of care for venous thromboembolism (VTE) could not only benefit patient outcomes but also significantly expand the company's market share. The implications of such clinical advancements are substantial, potentially leading to a stronger competitive position and partnerships within the healthcare sector.

Market Research Analyst

Examining Inari Medical's commercial traction across emerging therapies and international expansion, it is evident that the company is working to diversify its revenue streams and reduce reliance on any single market or product line. The global commercial expansion and introduction of new products are likely drivers behind the reported revenue increase. This diversification strategy can shield the company from localized economic downturns and changes in regional healthcare policies.

The provided revenue guidance for 2024, with an expected growth of approximately 17.5% to 20.5%, suggests a confident yet conservative forecast, likely accounting for market uncertainties and the integration of new acquisitions. For stakeholders, this guidance, along with the anticipated profitability timeline, will be key indicators of the company's future performance and its ability to deliver on strategic initiatives.

IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023.

Fourth Quarter Financial and Recent Business Highlights

• Generated revenue of $132.1 million in Q4 of 2023, up 22.6% over the same quarter last year.
• GAAP operating loss was $9.3 million in Q4 of 2023, compared to a $5.9 million operating loss in the same quarter of last year.
• Non-GAAP operating loss was $0.3 million in Q4 of 2023, compared to a $5.9 million non-GAAP operating loss in the same quarter of last year.
• Closed LimFlow acquisition on November 15, 2023.
• Completed enrollment in the PEERLESS randomized controlled trial.
  

“Our solid fourth quarter performance was driven by strong underlying procedural growth and crisp execution across our three growth pillars led by our core VTE business, with meaningful contributions from emerging therapies and international geographies,” said Drew Hykes, CEO of Inari Medical. "We also closed on the acquisition of LimFlow in mid-November. In terms of clinical evidence generation, the completion of enrollment in PEERLESS, our first RCT, represents an important step forward in our commitment to generating the highest level of clinical evidence. Taken together, these efforts will result in the establishment of our therapy as the standard of care for VTE. With a strong VTE foundation and encouraging commercial traction across emerging therapies and international, we remain confident in our ability to generate sustainable growth for many years to come. Most importantly, we remain fully committed to advancing our mission of addressing major unmet needs for patients."

Fourth Quarter 2023 Financial Results
Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022. The increase over the prior year quarter was driven primarily by increased adoption of our procedures, new products, and global commercial expansion.

Gross profit was $115.1 million for the fourth quarter of 2023, compared to $94.6 million for the fourth quarter of 2022. Gross margin was 87.1% for the fourth quarter of 2023, compared to 87.8% for the fourth quarter of 2022.

Operating expenses for the fourth quarter of 2023 were $124.4 million, compared to $100.5 million for the fourth quarter of 2022. The increase was mainly driven by transaction costs associated with the acquisition of LimFlow; personnel-related expenses, including commissions and stock-based compensation associated with increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations; sales and marketing related efforts; and amortization expense related to an intangible asset acquired in the LimFlow acquisition.

GAAP operating loss was $9.3 million in the fourth quarter of 2023, compared with a $5.9 million GAAP operating loss for the fourth quarter of 2022.

Non-GAAP operating loss was $0.3 million in the fourth quarter of 2023. The following items were excluded from the non-GAAP operating loss: acquisition-related costs of $7.7 million and acquired intangible asset amortization of $1.3 million. There were no non-GAAP adjustments related to the company’s operating loss for the fourth quarter of 2022.

Net loss was $4.7 million for the fourth quarter of 2023 and net loss per share was $0.08 on a weighted-average basic and diluted share count of 57.6 million, compared to a net loss of $5.8 million and a net loss per share of $0.11 on a weighted-average basic and diluted share count of 53.6 million, in the same period of the prior year.

Full Year 2023 Financial Results
Revenue was $493.6 million for the year ended December 31, 2023, up 28.7% compared to $383.5 million in the prior year. The increase over the prior period was driven primarily by continued U.S. and international commercial expansion, increased adoption of our procedures, and introduction of new products.

Gross profit was $434.6 million for the full year of 2023, compared to $339.0 million for the prior year. Gross margin was 88.0% for the full year of 2023, compared to 88.4% for the prior year.

Operating expenses for the full year of 2023 were $448.6 million, compared to $367.1 million for the prior year. The increase was mainly driven by personnel-related expenses, including commissions and stock-based compensation associated with increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.

GAAP operating loss was $14.0 million for the full year of 2023, compared with a $28.1 million GAAP operating loss in the prior year.

Non-GAAP operating loss was $2.4 million for the full year of 2023. The following items were excluded from the non-GAAP operating loss: acquisition-related costs of $10.4 million and acquired intangible asset amortization of $1.3 million. There were no non-GAAP adjustments related to the company’s full year 2022 operating loss.

Net loss was $1.6 million for the full year of 2023 and net loss per share was $0.03 on a weighted-average basic and diluted share count of 56.8 million, compared to a net loss of $29.3 million and net loss per share of $0.55 on a weighted-average basic and diluted share count of 52.8 million.

Full Year 2024 Revenue Guidance

• Inari expects full year 2024 revenue of $580 million to $595 million, reflecting growth of approximately 17.5% to 20.5% over 2023.
• The company still expects to reach sustained operating profitability in the first half of 2025.

Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the fourth quarter and full year 2023 financial results and acquisition of LimFlow after market close on February 28, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live by dialing (844) 825-9789 for domestic callers or (412) 317-5180 for international callers. The live webinar and presentation may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com.

Use of Non-GAAP Financial Measures
This press release contains references to non-GAAP operating income (loss), which is considered a non-GAAP financial measure. This means that non-GAAP operating income (loss) is determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). As used by Inari, non-GAAP operating income (loss) excludes from GAAP operating income (loss) the following items: amortization of acquired intangible assets and acquisition-related costs. Beginning in the fourth quarter of 2023, we began presenting non-GAAP operating income (loss) to exclude these charges because we believe these charges are significantly impacted by the timing and valuation of acquisitions, such as our LimFlow acquisition in the fourth quarter of 2023. Our management believes the presentation of non-GAAP operating income (loss) is useful because it provides meaningful comparisons to prior periods and provides visibility to our underlying operating performance and an additional means to evaluate the cost and expense trends excluding the impact of these acquisition-related items, which are not related to our core business operations.

Our definition of non-GAAP operating income (loss) may differ from similarly titled measures used by others. Non-GAAP operating income (loss) should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. We encourage investors to review the reconciliation of non-GAAP operating income (loss) to GAAP operating income (loss), which has been provided in the financial statement tables included in this press release.

About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease, and beyond. We are just getting started.

Forward Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include expectations regarding Inari’s core business, its ability to integrate LimFlow, expectations regarding future growth, Inari's ability to meet customers' needs, and timing for achieving sustained operating profitability, and are based on Inari’s current expectations, forecasts, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2023, and in Inari’s other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:
John Hsu, CFA
VP, Investor Relations
949-658-3889
IR@inarimedical.com

INARI MEDICAL, INC.
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
	Three Months Ended December 31,								Years ended December 31,
	2023				2022				2023				2022
Revenue	$	132,094			$	107,771			$	493,632			$	383,471
Cost of goods sold		17,006				13,128				59,068				44,506
Gross profit		115,088				94,643				434,564				338,965
Operating expenses
Research and development		22,892				20,412				87,533				74,221
Selling, general and administrative		101,495				80,122				361,063				292,843
Total operating expenses		124,387				100,534				448,596				367,064
Loss from operations		(9,299	)			(5,891	)			(14,032	)			(28,099	)
Other income (expense)
Interest income		2,714				970				15,613				1,852
Interest expense		(69	)			(74	)			(196	)			(294	)
Other income		3,478				187				2,861				356
Total other income		6,123				1,083				18,278				1,914
(Loss) income before income taxes		(3,176	)			(4,808	)			4,246				(26,185	)
Provision for income taxes		1,491				990				5,882				3,082
Net loss	$	(4,667	)		$	(5,798	)		$	(1,636	)		$	(29,267	)
Other comprehensive income (loss)
Foreign currency translation adjustments		10,002				222				9,864				(592	)
Unrealized gain (loss) on available-for-sale debt securities		41				1,572				(1,828	)			1,843
Total other comprehensive income		10,043				1,794				8,036				1,251
Comprehensive income (loss)	$	5,376			$	(4,004	)		$	6,400			$	(28,016	)
Net loss per share
Basic	$	(0.08	)		$	(0.11	)		$	(0.03	)		$	(0.55	)
Diluted	$	(0.08	)		$	(0.11	)		$	(0.03	)		$	(0.55	)
Weighted average common shares used to compute net loss per share
Basic		57,639,591				53,610,347				56,770,657				52,837,674
Diluted		57,639,591				53,610,347				56,770,657				52,837,674

INARI MEDICAL, INC.
Consolidated Balance Sheets
(in thousands, except share data)
	December 31, 2023				December 31, 2022
Assets
Current assets
Cash and cash equivalents	$	38,597			$	60,222
Restricted cash		611				—
Short-term investments in debt securities		76,855				266,179
Accounts receivable, net		70,119				58,611
Inventories, net		42,900				32,581
Prepaid expenses and other current assets		6,481				5,312
Total current assets		235,563				422,905
Property and equipment, net		20,929				21,655
Operating lease right-of-use assets		48,407				50,703
Goodwill		214,335				—
Intangible assets		150,884				—
Deposits and other assets		4,117				8,889
Total assets	$	674,235			$	504,152
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	10,577			$	7,659
Payroll-related accruals		48,706				38,955
Accrued expenses and other current liabilities		15,364				8,249
Operating lease liabilities, current portion		1,692				1,311
Total current liabilities		76,339				56,174
Operating lease liabilities, noncurrent portion		30,355				30,976
Deferred tax liability		36,231				—
Other long-term liability		66,400				—
Total liabilities		209,325				87,150
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022		—				—
Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,762,414 and 54,021,656 shares issued and outstanding as of December 31, 2023 and 2022, respectively		58				54
Additional paid in capital		504,453				462,949
Accumulated other comprehensive income		8,885				849
Accumulated deficit		(48,486	)			(46,850	)
Total stockholders' equity		464,910				417,002
Total liabilities and stockholders' equity	$	674,235			$	504,152

INARI MEDICAL, INC.
Reconciliation of GAAP Operating Loss to Non-GAAP Operating Loss
(in thousands)
(Unaudited)
	Three Months Ended December 31,								Years ended December 31,
	2023				2022				2023				2022
GAAP Operating loss	$	(9,299	)		$	(5,891	)		$	(14,032	)		$	(28,099	)
Non-GAAP Adjustments:
Amortization of acquired intangible assets		1,255				—				1,255				—
Acquisition-related expense (a)		7,725				—				10,406				—
Non-GAAP Operating loss	$	(319	)		$	(5,891	)		$	(2,371	)		$	(28,099	)

________________

(a) For three months ended December 31, 2023, acquisition related expenses included $6.0 million of transaction costs and $1.7 million of severance and integration related expenses. For the year ended December 31, 2023, acquisition related expenses included $8.7 million of transaction costs and $1.7 million of severance and integration related expenses.

Revenue Disaggregation

Commencing in the fourth quarter of 2023, we began presenting revenue bifurcated between VTE and Emerging Therapies. The following table presents the amount of revenue in VTE and Emerging Therapies recognized for the periods presented (in thousands, unaudited):

	Three Months Ended  December 31,			Three Months Ended  September 30,			Three Months Ended  June 30,			Three Months Ended  March 31,
	2023			2023			2023			2023
VTE	$	126,671		$	121,460		$	114,086		$	114,058
Emerging Therapies		5,423			4,906			4,919			2,109
Total Revenue	$	132,094		$	126,366		$	119,005		$	116,167

	Three Months Ended December 31,			Three Months Ended September 30,			Three Months Ended June 30,			Three Months Ended March 31,
	2022			2022			2022			2022
VTE	$	105,978		$	95,980		$	92,721		$	86,752
Emerging Therapies		1,793			224			23			—
Total Revenue	$	107,771		$	96,204		$	92,744		$	86,752

What was Inari Medical's revenue in Q4 2023?

In Q4 2023, Inari Medical reported revenue of $132.1 million, a 22.6% increase over the same quarter in 2022.

What was Inari Medical's GAAP operating loss in Q4 2023?

In Q4 2023, Inari Medical had a GAAP operating loss of $9.3 million, compared to $5.9 million in Q4 2022.

What was Inari Medical's non-GAAP operating loss in Q4 2023?

In Q4 2023, Inari Medical reported a non-GAAP operating loss of $0.3 million, compared to $5.9 million in Q4 2022.

When did Inari Medical close the LimFlow acquisition?

Inari Medical closed the LimFlow acquisition on November 15, 2023.

What trial did Inari Medical complete enrollment in?

Inari Medical completed enrollment in the PEERLESS randomized controlled trial.

What was Inari Medical's revenue for full year 2023?

In 2023, Inari Medical reported revenue of $493.6 million, a 28.7% increase over the prior year.

What is Inari Medical's revenue guidance for full year 2024?

Inari Medical expects revenue of $580-595 million for full year 2024.

When does Inari Medical aim to achieve sustained operating profitability?

Inari Medical aims to reach sustained operating profitability in the first half of 2025.